CPT code 0629T identifies a CT-guided injection of a cellular or tissue–based product into a lumbar intervertebral disc for the first level treated. This emerging interventional procedure is notable nationally as biologic and regenerative spinal therapies expand, creating new coverage, coding, and utilization considerations across major payers. Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what the code represents, payer coverage patterns, and the clinical context for use of CT guidance and lumbar disc targeting. The publication outlines common billing modifiers and service-line placement, explains typical sites of service, and summarizes benchmarks and reimbursement policy trends affecting adoption and coverage decisions. It also highlights operational considerations for coding the first disc level treated and how bilateral vs unilateral injections are represented under this code.

Data not available in the input is noted where specific payer policy details, associated taxonomies, ICD-10 diagnoses, and related codes would normally be provided. The focus remains on national implications for payers and providers considering CT-guided cellular or tissue–based lumbar disc injections.